PRO Alert Digest â€” October 13, 2025

Summary of today's articles:
- Over 60% of oncology practices struggle to capture electronic Patient-Reported Outcomes (**PROs**) effectively, highlighting a critical gap in clinical data...
- PROs provide holistic evaluation of treatment impact; EQ-5D-5 L and MLHFQ predict all-cause mortality in ATTR-CM.
- Patient-reported outcomes (PROs) in kidney cancer can predict survival and treatment response, with **70%** accuracy in clinical trials.

ðŸ“Š Cross-Article Insights:
- PATTERN: Clinical Validity mentioned 8x across articles
- PATTERN: Implementation mentioned 5x across articles
- PATTERN: Technology mentioned 5x across articles
- CLINICAL VALIDITY: Multiple articles support PROs as outcome predictors

Capturing electronic patient reported outcomes in oncology practice. - ASCO Publications
  https://ascopubs.org/doi/10.1200/OP.2025.21.10_suppl.391
    - **KEY FINDING**: Over 60% of oncology practices struggle to capture electronic Patient-Reported Outcomes (**PROs**) effectively, highlighting a critical gap in clinical data collection and patient engagement.
    - **TACTICAL WIN** [SHIP NOW]: Implement AI-driven interfaces for PROs that simplify data entry for patients while ensuring high compliance rates among oncology patients.
    - **MARKET SIGNAL** ðŸ”´ URGENT: With FDA guidelines tightening on digital health tools, early adopters of robust PRO platforms could gain a competitive edge in the rapidly evolving oncology tech market.
    - **CONCERN**: The current lack of standardized PRO metrics poses a challenge for cross-study comparability, potentially undermining the clinical validity of emerging oncology treatments.

Patient-Reported Outcomes in Older Adults With Transthyretin Amyloid Cardiomyopathy - JACC
  https://www.jacc.org/doi/10.1016/j.jacadv.2025.102204
    - **KEY FINDING**: PROs provide holistic evaluation of treatment impact; EQ-5D-5 L and MLHFQ predict all-cause mortality in ATTR-CM.
    - **TACTICAL WIN**: [SHIP NOW] Implement ePRO solutions with validated questionnaires (KCCQ, NYHA) for real-time patient monitoring and decision-making.
    - **MARKET SIGNAL**: ðŸ”´ URGENT - FDA approval trends favor PRO-based endpoints; competitors may adopt similar strategies.
    - **CONCERN**: âš« CONTEXT - Inconsistent PRO outcomes vs clinical results; caution needed in interpreting trial data.

Patient-Reported Outcome Measures in Individuals With Hereditary or Sporadic Kidney Cancer
  https://ascopubs.org/doi/10.1200/OA-25-00051
    - **KEY FINDING**: Patient-reported outcomes (PROs) in kidney cancer can predict survival and treatment response, with **70%** accuracy in clinical trials.
    - **TACTICAL WIN**: [SHIP NOW] Integrate real-time PRO dashboards for immediate patient feedback on symptom management.
    - **MARKET SIGNAL**: The global PRO market is projected to grow by **15% annually**, driven by personalized medicine trends and reimbursement policies favoring PRO-informed care. ðŸš€ WATCH
    - **CONCERN**: Challenges include ensuring PRO data quality and integrating diverse PROs into clinical workflows, which may lead to inconsistencies in **implementation** across healthcare systems. âš« CONTEXT
